Background. Non-IgA mesangioproliferative glomerulonephritis is a well recognized but less studied entity. The clinical manifestations, treatment response and long-term outcome have not been clearly defined.
Introduction
IgA nephropathy, which is characterized by mesangioproliferative nephritis with IgA deposits, is considered to be the most common primary glomerular disease worldwide. The spectrum of clinical presentation, treatment response, prognostic markers and long-term outcome is well-known. Mesangioproliferative glomerulonephritis can also occur without deposition of IgA. Mesangioproliferative glomerulonephritis without IgA deposits is less well described in 2322 C. Couchoud et al.
the literature. This entity appears to be prevalent mainly in the developing countries. Their clinical presentation, prognostic markers and treatment response have not been elaborately described and the long-term outcome is also not clear. Non-IgA mesangioproliferative glomerulonephritis is not an uncommon entity and has been reported in many developing countries [1] [2] [3] [4] [5] [6] . In a biopsy registry data from south India, non-IgA mesangioproliferative glomerulonephritis comprised 11.3 and 7.3% of all biopsy-proven renal disease in children and adults, respectively [2] . In this study, we present our centre's experience on non-IgA mesangioproliferative glomerulonephritis with emphasis on their clinical profile, treatment response and long-term outcome.
Materials and methods

Patients
This study was conducted at the department of nephrology IPGMER, Kolkata, a tertiary referral centre in eastern India. From July 2000 to July 2008, 116 patients were diagnosed as non-IgA mesangioproliferative glomerulonephritis. Out of these original cohorts, fifty-seven patients were followed-up for >36 months and were included in this study.
Patients were followed-up every 2 weeks for the first 2 months and then monthly until 6 months after which they were evaluated at 3 monthly intervals. During each visit, patients were assessed for their renal function and their degree of proteinuria in 24-h urine samples. Renal function was assessed by serum creatinine and creatinine clearance. Adverse events if present were noted. Complete remission (CR) was defined as proteinuria <500 mg in a 24-h sample. Partial remission was defined as reduction of proteinuria by >50% from baseline and <3 g/24 h. No remission was defined as failure of reduction of proteinuria from baseline or persistent nephrotic range proteinuria.
Pathological diagnosis
Non-IgA mesangioproliferative glomerulonephritis was defined as those who had features of mesangial hypercellularity or/and increase in mesangial matrix on light microscopy with negative IgA deposits on immunofluorescence. Mesangial hypercellularity was defined as presence of more than four mesangial cell per area. They were graded as mild, moderate or severe. Only those who had mesangial hypercellularity without any endocapillary proliferative changes were included in this study.
If the mesangial hypercellularity affected <50% of the total number of glomeruli, then it was considered focal mesangial proliferative nephritis. Those with >50% of glomerular involvement were considered as diffuse mesangioproliferative lesions.
For each single glomerular mesangial proliferation involving >50% was considered as global, while proliferation involving <50% of glomerular area was considered as segmental.
Presence of cellular crescents/fibrous crescents, glomerulosclerosis and focal synechiae were noted.
Interstitial infiltrate were semi-quantitatively graded as none, mild, moderate and severe.
Tubular atrophy was graded as T0: no evidence of tubular atrophy, T1: atrophy involving <25% and T2: atrophy affecting >25%.
Interstitial fibrosis was graded as IF0: no degree of interstitial fibrosis, IF1: <25% of interstitial fibrosis and IF2: >25% involvement of interstitial fibrosis.
Vessel involvement were graded as V0: no evidence of sclerosis and V1: evidence of sclerosis.
Haematuria was graded as: Grade 0: <6 red blood cells (RBC) per high power field (h.p.f.), Grade 1: 6-15 RBC per h.p.f., Grade 2: 15-30 RBC per h.p.f. and Grade 4: >30 RBC per h.p.f.
Treatment
For adults with nephrotic syndrome at presentation. Steroid was given at a dosage of 60 mg/m 2 on a daily basis for 6 weeks and then it was changed to an alternate day basis and tapered off. Steroid resistance was defined as absence of remission even after having received steroid at 60 mg/m 2 for 16 weeks.
For children. Steroid was initiated at 2 mg/kg on a daily basis for 6 weeks and then followed by 1.5 mg/kg on alternate days for another 6 weeks and then stopped. Steroid resistance was defined as absence of remission even after 2 mg/kg for 4 weeks in accordance with the Indian paediatric nephrology guidelines [7] . Steroid dependence was defined as the presence of at least two consecutive relapses while on alternate day steroid or within 2 weeks of steroid discontinuation.
Patients who were steroid dependent with steroid toxicity features were treated with either levamisole, cyclophosphamide, tacrolimus or mycophenolate mofetyl (MMF). Until 2007, levamisole or cyclophosphamide was commonly used. After 2007, tacrolimus/mycophenolate was used in such patients.
Those patients who were steroid resistant were treated with either cyclophosphamide, tacrolimus or MMF.
Tacrolimus was started at 0.1 mg/kg with a target trough level (T0) at 5-10 ng/mL for the first 2 months and 3-7 ng/mL for the remaining months. Usual duration of therapy was 12-18 months. Cyclophosphamide was given at 1.5-2.5 mg/kg for 12 weeks. Dosing of mycophenolate was started at 1-1.5 g in divided doses. Levamisole was intiated at 2-2.5 g/kg on alternate days and initially given for 3 months and continued for another 18 months. If the patient relapsed while on levamisole then it was discontinued and another immunosuppressive agent was used.
Statistical analysis
Statistical analysis was done using SPSS statistical software package. Data were presented as mean AE SD for normally distributed continuous variables and as median (range) for continuous variables not having a normal distribution.
Correlation testing was performed using Pearson's coefficient for continuous variables distributed normally A P-value of <0.05 was considered statistically significant, and all tests were two tailed. Multiple regression analysis was done using stepwise method.
Results
Baseline patient characteristics
Mean age at presentation was 31 years AE 13.78. It affected males nearly twice as common as females. There were only two children under age of 12.
Haematuria. Haematuria was noted in 22/57 (38.5%) and was macroscopic in nine patients (15.7%) and microscopic in 13 patients (22.8%). Twelve of the 13 patients with macroscopic haematuria also had nephrotic range proteinuria, whereas in 1 patient, proteinuria was sub-nephrotic.
Proteinuria. The mean 24-h urinary protein at presentation was 4.19 AE 2.8 g. Nephrotic syndrome was noted in 47/57 (82.1%) at diagnosis. Of these 47 patients, 13 had evidence of renal dysfunction (as defined by serum creatinine >1.5 mg/dL).
Other modes of presentation. Other presenting features include sub-nephrotic proteinuria in 5/57 (8.9%), acute kidney injury(AKI)/rapidly progressive renal failure (RPRF) in another five patients (8.9%).
Overall mean serum creatinine at presentation was 1.45 AE 0.84 mg/dL. Hypertension was noted in 17 patients (30.3%). Mean systolic blood pressure (SBP) was 135.86 AE 22.16 and mean diastolic blood pressure (DBP) was 85 AE 15.65 mmHg.
Baseline pathological characteristics. The mean number of glomeruli were 13.5 AE 9.7. Degree of mesangial hypercellularity was noted as mild in 49/57 (85.9%), moderate in 7/57(12.2%) and severe in 1/57(1.7%).
Diffuse involvement of glomeruli was noted in 38/57 (66.9%) and focal in 19/57 (33.1%) patients.
Interstitial infiltrates were scored as none in 17/57(29.8%), mild in 24/57(42.1%), moderate in 14/57(24.5%) and severe in 2/57 (3.5%).
T0, T1, T2 score were seen in 46/57 (82.1%), 9/57 (16.1%) and 2/57 (1.8%).
Interstitial fibrosis score were noted as IF0 in 53/57 (93%) and IF1 in 4/57 (7%) patients. Vessel sclerosis was noted in 5/57 (8.7%), while it was absent in 52/57(91.3%).
Immune deposits were noted in 34/57 (59.6%) and absent in 23/57 (40.4%). IgG, IgM, C3, C1q staining were present in 30/57 (52.6%), 15/57 (26.3%), 11/57 (19.2%) and 1/57 (1.7%). Median time to biopsy from onset was 2.5 months (range 0-150).
Twenty-three of the 57 patients did not have any immune deposits on immunofluorescence staining. The clinical characteristics of these patients as compared to those with immune deposits are as shown in Table 1 .
Treatment response
Nephrotic syndrome. In total, 51 patients developed nephrotic syndrome (47 had nephrotic syndrome at presentation, while 4 patients who had sub-nephrotic proteinuria or acute kidney injury at presentation later developed nephrotic syndrome). Thirty-four of 51 (66.7%) responded to steroid treatment and had either no relapse or infrequent relapse, 8/51 (15.6%) had steroid-dependent nephrotic syndrome (SDNS) and 9/51 (17.6%) were steroid resistant.
Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) were used in 87.7% of the patients, calcium channel blocker in 7% and beta blockers in 19.2%. Steroid-dependent nephrotic syndrome. Eight patients had SDNS. The treatment response and outcome of these patients are as illustrated in Figure 1 . In total, seven patients ultimately received tacrolimus. The response to tacrolimus was achieved in all seven patients. At last follow-up, two of these patients were still in remission after having discontinued tacrolimus 1-year after therapy. Mycophenolate failed to prevent relapse in the two cases where it was tried. The addition of levamisole to steroids also failed to provide any beneficial effect. Steroid-resistant nephrotic syndrome. Nine patients were steroid resistant, out of which three progressed to end-stage renal disease (ESRD).
In total, four patients received tacrolimus (including one with cyclophosphamide resistance), CR was attained in one and partial response achieved in two patients. One patient did not respond to tacrolimus and had to be discontinued after 3 months.
MMF was given in two of these patients. CR was achieved in one patient but relapsed again within 2 years of discontinuation of the drug. One patient did not respond to MMF.
Three patients received oral cyclophosphamide for 3 months. None of these attained remission. One of these patients subsequently received tacrolimus and achieved remission.
One patient received azathioprine for 3 months with partial response, and the drug had to be discontinued following development of pulmonary tuberculosis.
Sub-nephrotic proteinuria
Of the five patients who had sub-nephrotic proteinuria at presentation, three progressed to nephrotic range proteinuria, while in two patients, proteinuria remained persistent but in sub-nephrotic range. All these patients had received ACEI and/or ARB and/or spironolactone.
Acute kidney injury
Of the five patients who presented with acute kidney injury, four patients recovered normal renal function and were doing well until the last follow-up. One patient went on to develop nephrotic syndrome on subsequent follow-up.
Worsening of kidney function
Progression of disease was noted in 13 patients. Three patients developed ESRD, all of whom were steroid resistant. At last follow-up, three patients were in CKD 4 and another seven patients in CKD 3.
The treatment response did not differ based on the presence or absence of immune deposits ( Table 2) .
Predictors of outcome
Since the representation of patients with acute kidney injury and sub-nephrotic proteinuria were small, correlations were performed only for those patients who had presented with or developed nephrotic syndrome. The outcome measure considered was serum creatinine at 36 months.
There was no significant correlation between age at onset, sex of the patient, degree of proteinuria at presentation, presence or absence of haematuria, presence or absence of hypertension with serum creatinine at 36 months. The response to steroid therapy had significant correlation with serum creatinine at 36 months (r ¼ À0.446, P-value < 0.001).
On histological evaluation, the presence of fibrous crescents (r ¼ 0.55, P < 0.001) and C3 deposits (r ¼ 0.41, P-value < 0.001) on immunofluorescence microscopy had a significant correlation with serum creatinine at 36 months. Presence of glomerulosclerosis, focal or diffuse involvement, severity of mesangial proliferation, presence of focal synechiae, degree of tubular atrophy, interstitial infiltrates did not have any correlation with the serum creatinine at 36 months.
Multiple regression analysis was performed using stepwise method using fibrous crescents, presence of C3 deposits and steroid response as the independent variable and serum creatinine at 36 months as the dependent variable which showed adjusted R 2 0.341 (P-values 0.017, 0.008 and 0.004, respectively). Thus, C3 deposits, presence of fibrous crescents and lack of treatment response to steroid seem to be poor prognostic markers.
Adverse events
The adverse events associated are as depicted in Table 3 .
Discussion
Non-IgA mesangioproliferative glomerulonephritis is not an uncommon glomerulopathy in developing countries. Its prevalence varies in different registries as shown in Table 4 [2, [8] [9] [10] [11] . However, the clinical course and longterm outcome remains largely undefined. This may be because it is often considered not as a distinct entity but rather a 'box' for different pathological conditions, including IgM nephropathy or peri-infectious glomerulonephritis. In this context, it is important to note that a significant number of our patients (23/57) did not have any immune deposits on immunofluorescence staining. The baseline characteristics of these patients did not differ significantly from those who had immune deposits except for the degree of mesangial proliferation.
In a retrospective study from Norway with a median follow-up of 34.8 months, it was reported that the progression to ESRD was similar for both IgA and Non-IgA mesangioproliferative glomerulonephritis [9] . The 3-year renal survival was 93%. More recently, Owada et al. [12] reported the outcome of 84 non-IgA mesangioproliferative glomerulonephritis patients followed-up for 3.125 AE 1.91 years. These patients did not receive any medications and the renal function was stable at the end of the follow-up. The authors concluded that non-IgA mesangioproliferative glomerulonephritis is a benign entity.
The results of our study are significantly different from the study of Owada et al. [12] . This may be due to differences in the baseline characteristics of the patients. Our patient cohort had more severe proteinuria (4.19 g as compared to 0.5 g) with higher degree of renal dysfunction (1.45 as compared to 0.89 mg/dL). Most of our patients required steroids and ACEIs. Steroid resistance occurred in nearly 18% of patients with nephrotic syndrome. The prognosis was poor for this sub-group, with one-third of them progressing to ESRD. Overall, 13 patients (22.8%) developed progressive loss of glomerular filtration rate with 3 developing ESRD (5%), another 3 were in CKD 4(5%) and 7 patients in CKD Stage 3 (12.2%).
In their retrospective study, Vickse et al. [9] found that entry creatinine, proteinuria >1 g at presentation, SBP >160, DBP >90 mmHg, low serum albumin and age >60 years to be clinical predictors of progression to ESRD. Histologically, presence of mesangial sclerosis, increased interstitial scores, focal crescents, necrosis and nephrosclerosis were predictors of progression to ESRD.
In our study, none of the clinical parameters taken into account at presentation including age at onset, presence of haematuria, degree of proteinuria, serum creatinine, time to biopsy or presence of hypertension correlated with the renal function at 36 months. Histologically, only the presence of fibrous crescents and presence of C3 deposits correlated with serum creatinine at 36 months. The reason for this discrepancy could be due to the smaller sample size of our study as well as the under representation of patients with chronic features on biopsy. Only 18% of our patients had features of tubular atrophy and 8% had features of interstitial fibrosis. This could be because biopsy was performed quite early compared to other studies (2.5 months compared to 22 months [9] , 7.38 years [12] ). Response to steroid therapy correlated with renal function at 36 months (P-value < 0.001). All of those patients who developed ESRD were steroid resistant and also resistant to other immunosuppressive agents.
We did observe that steroid-dependent patients seem to respond better to tacrolimus than mycophenolate, although the number of patients receiving them was too small to come to any definite conclusions. Probably, a randomized controlled trial may help to clarify the situation.
The strength of our study lies in the meticulous followup protocol extending over a prolonged period. Consequently, we were able to monitor the disease progression, treatment response as well as the side effects with greater accuracy. However, there are a number of limitations in our study. The number of patients presenting with asymptomatic proteinuria is quite small and this under representation could have led to poorer outcome as observed. The reason for this could have been referral bias. Secondly, the overall number of patients included in this study is quite small. We also did not perform electron microscopy in these patients and our inference of lack of immune deposits was based on the immunofluorescence microscopy findings. False-negative immune deposits on immunofluorescence may occur.
Thus, to conclude, in our experience, non-IgA mesangioproliferative glomerulonephritis is not a benign entity and can lead to progressive renal injury ultimately requiring renal replacement therapy. Its treatment is also associated with significant morbidity and serious side effects. Poor response to steroid, presence of fibrous crescent and C3 deposits are poor prognostic markers. The clinical features at presentation, treatment response and long-term outcome are not affected by the presence or absence of mesangial deposits. A larger prospective study would be required to assess the prognostic factors in such patients, so that optimal use of immunosuppressive therapy could be achieved with minimal side effects.
